Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $68.00 Consensus Price Target from Brokerages

19 Sep 2026, 05:58 by Kim Johansen · The Markets Daily

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $68.00.

Several analysts have commented on the stock. HC Wainwright raised their price objective on shares of Travere Therapeutics from $57.00 to $67.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Evercore set a $78.00 price target on shares of Travere Therapeutics in a report on Monday, August 10th. Weiss Ratings cut shares of Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Citigroup raised their price target on shares of Travere Therapeutics from $70.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, Guggenheim upped their price objective on Travere Therapeutics from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th.

Get Our Latest Research Report on TVTX

Key Stories Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

Positive Sentiment: Analysts maintain a generally favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $68. Several firms have raised their targets to $70-$78, suggesting potential upside from recent trading levels. Travere Therapeutics analyst coverage
Positive Sentiment: Institutional interest has increased, including new positions from Jupiter Topco and Bank of America, while Wellington Management and Perceptive Advisors expanded their holdings. The buying may reinforce confidence in Travere’s commercial prospects and rare-disease pipeline.
Neutral Sentiment: Travere will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on FILSPARI and the company’s pipeline, although no new business information was announced. Travere presentation announcement
Negative Sentiment: Multiple executives and insiders reported selling shares, including CEO Eric Dube, CFO Christopher Cline, CAO Sandra Calvin and several executive vice presidents. Collectively, the disclosed transactions represented roughly $61 million of stock sales, with individual holdings falling by approximately 6% to 60%. The trades were conducted under pre-arranged Rule 10b5-1 plans, which lessens their signaling value, but the concentration of selling may still weigh on investor sentiment and near-term momentum.

Insider Buying and Selling

In other news, EVP Jula Inrig sold 44,674 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total transaction of $2,784,977.16. Following the sale, the executive vice president owned 100,491 shares of the company’s stock, valued at $6,264,608.94. This trade represents a 30.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Peter Heerma sold 8,282 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $65.07, for a total transaction of $538,909.74. Following the transaction, the executive vice president directly owned 117,066 shares of the company’s stock, valued at $7,617,484.62. The trade was a 6.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,050,294 shares of company stock worth $66,336,443 in the last three months. 4.44% of the stock is currently owned by company insiders.

Institutional Trading of Travere Therapeutics

Several large investors have recently modified their holdings of the company. Jupiter Topco LLC bought a new position in shares of Travere Therapeutics in the 2nd quarter worth approximately $643,299,000. Bank of America Corp DE purchased a new position in shares of Travere Therapeutics in the second quarter worth approximately $259,527,000. Perceptive Advisors LLC grew its position in Travere Therapeutics by 12.7% during the fourth quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company’s stock valued at $163,469,000 after buying an additional 483,565 shares during the period. Wellington Management Group LLP grew its position in Travere Therapeutics by 50.0% during the second quarter. Wellington Management Group LLP now owns 1,533,080 shares of the company’s stock valued at $87,094,000 after buying an additional 510,808 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Travere Therapeutics by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 2,143,495 shares of the company’s stock valued at $81,915,000 after buying an additional 5,465 shares during the last quarter.

Travere Therapeutics Stock Down 3.1%

Shares of NASDAQ:TVTX opened at $62.76 on Wednesday. The stock has a market capitalization of $5.92 billion, a P/E ratio of -136.43 and a beta of 1.05. The stock’s 50-day moving average price is $61.76 and its 200-day moving average price is $48.60. The company has a current ratio of 4.05, a quick ratio of 3.99 and a debt-to-equity ratio of 24.58. Travere Therapeutics has a 12-month low of $22.06 and a 12-month high of $68.73.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.03. The company had revenue of $169.58 million during the quarter, compared to analysts’ expectations of $157.27 million. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%.Travere Therapeutics’s quarterly revenue was up 48.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.13 EPS. On average, equities analysts anticipate that Travere Therapeutics will post -0.54 earnings per share for the current year.

About Travere Therapeutics

(Get Free Report)

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.